FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Antibodies are disclosed, which are chimeric, CDR-transplanted and humanized antibodies with high affinity to hIL-13 and neutralizing activity of hIL-13 in vitro and in vivo. Method of obtaining and using antibodies according to invention is disclosed.
EFFECT: antibodies, or parts of antibodies under the invention can be used for detection of hIL-13 and for inhibiting hIL-13 activity, for example, in human suffering from violation, in which hIL-13 activity negatively affects patient's health.
36 cl, 23 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
METHODS AND COMPOSITIONS FOR ASTHMA TREATMENT USING ANTIBODIES AGAINST IL-13 | 2012 |
|
RU2640025C2 |
HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
IMMUNOGLOBULINS | 2005 |
|
RU2404192C2 |
THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
IL-13 RECEPTOR ALPHA 1 ANTIBODIES AND THEIR APPLICATION | 2006 |
|
RU2413736C2 |
MONOCLONAL ANTIBODIES AGAINST PROTEIN RGM A AND APPLICATION THEREOF | 2009 |
|
RU2524136C2 |
ADVANCED GLYCATION END PRODUCT (RAGE) RECEPTOR ANTIBODIES AND USING THEM | 2009 |
|
RU2518351C2 |
Authors
Dates
2016-12-20—Published
2012-10-04—Filed